Mesenchymal Stem Cells to Treat Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.
Also called NCT02302599
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 103 participants
- Sponsor
- Registry
-
NCT02302599
-
- Other papers using this trial's data
- Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02302599. Randomized; quadruple masking; primary purpose treatment. Start 2013-01 (actual); primary completion 2020-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Mesenchymal Stem Cells to Treat Type 2 Diabetes
- Acronym
- UC-MSCs
- Condition
- Type 2 Diabetes
- Condition
- Mesenchymal Stem Cells
- Intervention (Biological)
- Umbilical cord mesenchymal stem cells
- Intervention (Biological)
- Controlled suspension liquid
- Lead sponsor
- Chinese PLA General Hospital
Record details
- Record id
cardio:ct-nct02302599- Content hash
99f1bc57cfa9e8e3e38bd30d805194780a61180a8ed10217dd1659efde4312a8